20-185 - A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
Status: openThis project is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory track illness in infants. Pregnant women will be given a stabilized RSV prefusion F subunit vaccine or placebo during late 2nd trimester or early 3rd trimester of pregnancy. There will be infant follow-up for 24 months.
Prevent respiratory syncytial virus (RSV) disease by immunizing pregnant women
Contact Us
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by phone at 251-415-1598 or by email at marmistead@health.southalabama.edu.
Description
This study evaluates the use of Digoxin immune fab in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
Sponsors
This trial is sponsored by Pfizer.Providers Associated With This Trial
Sub Investigators
![Tracy Roth]()
View ProfileTracy Y. Roth, M.D.Obstetrician/GynecologistResidency Program Director for Obstetrics and Gynecology; Assistant Professor of Obstetrics and Gynecology; Focused Practice Designation in Pediatric and Adolescent Gynecology![Benjamin Estrada]()
View ProfileBenjamin Estrada, M.D.Pediatric Infectious DiseaseAssistant Dean for Educational Strategies and Faculty Development; Professor and Vice Chair of Pediatrics![Dr Holliday new head shot]()
View ProfileNicolette P. Holliday, M.D., F.A.C.O.G.Obstetrician/GynecologistAssociate Professor of Obstetrics and Gynecology/Focused Practice Designation in Pediatric and Adolescent Gynecology
